Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat

Autor: Eric J, Lawitz, Bal Raj, Bhandari, Peter J, Ruane, Anita, Kohli, Eliza, Harting, Dora, Ding, Jen-Chieh, Chuang, Ryan S, Huss, Chuhan, Chung, Robert P, Myers, Rohit, Loomba

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 21, iss 1

Background & aimsPatients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) are at high risk of morbidity and mortality. We previously found that a combination of the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929b2cef2b51a962b092040436babe79
https://escholarship.org/uc/item/1c44j6bg

Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis

Autor: Silvio Danese, Barrett G. Levesque, Brian G. Feagan, Alina Jucov, Bal Raj Bhandari, Rish K. Pai, Kristen Taylor Meadows, Brian J. Kirby, Jean‐Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J. Sandborn

Publikováno v: Alimentary pharmacologytherapeutics. 55(4)

Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbeeeba47992d26a8f01ee2037f6d3a3
https://pubmed.ncbi.nlm.nih.gov/35245958

A randomized, double-blind study to evaluate the safety and tolerability of KB174, a novel synthetic glycan, in patients with well-compensated cirrhosis

Autor: Bal Raj Bhandari, Jeffrey Cehelsky, Yan Zheng, Mark Wingertzahn, Norma Palma, Robert S Mittleman

Publikováno v: Journal of Hepatology. 73:S699

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69187c3042152b1b526e9f5c9fc3834e
https://doi.org/10.1016/s0168-8278(20)31858-4

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Autor: Catherine A.M. Stedman, Yanni Zhu, Sergio Borgia, Bernard Willems, Bal Raj Bhandari, Edward Gane, Kosh Agarwal, Jordan J. Feld, Evguenia S. Svarovskaia, Hadas Dvory-Sobol, Alexander J. Thompson, Gregory J. Dore, Graham R. Foster, Tarik Asselah, Diana M. Brainard, John G. McHutchison, Ronald Nahass, G. Mani Subramanian, Thomas Berg, Luisa M. Stamm, Ira M. Jacobson, Eric Lawitz, M. Davis, Stephen D. Shafran, Peter Ruane, Robert H. Hyland, Kimberly A. Workowski, Stuart K. Roberts, Brian L. Pearlman, Norbert Bräu

Publikováno v: Gastroenterology. 153(1)

Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8372ad2770cc69d118699d122cc153ae
https://pubmed.ncbi.nlm.nih.gov/28390869

Rifaximin has a Favorable Long-Term Safety Profile for Maintenance of Remission from Overt Hepatic Encephalopathy

Autor: Samuel H. Sigal, Arun J. Sanyal, Kunal Merchant, Nathan M. Bass, Fred Poordad, Muhammad Y. Sheikh, Ravikumar Vemuru, Audrey L. Shaw, Enoch Bortey, Todd Frederick, Kevin D. Mullen, Shirley Huang, Bal Raj Bhandari, William P. Forbes

Publikováno v: American Journal of Gastroenterology. 104:S136

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce90ab42758384769531dd2a4809f67f
https://doi.org/10.14309/00000434-200910003-00360